1. Registering for the Forum

    We require a human profile pic upon registration on this forum.

    After registration is submitted, you will receive a confirmation email, which should contain a link to confirm your intent to register for the forum. At this point, you will not yet be registered on the forum.

    Our Support staff will manually approve your account within 24 hours, and you will get a notification. This is to prevent the many spam account signups which we receive on a daily basis.

    If you have any problems completing this registration, please email support@jackkruse.com and we will assist you.

Autoimmune and the VDR vitamin d receptor

Discussion in 'Adrenal Rx and Leaky Gut Rx' started by chocolate, Apr 21, 2012.

  1. chocolate

    chocolate Silver

    http://mpkb.org/home/mp/stages



     
  2. chocolate

    chocolate Silver

  3. chocolate

    chocolate Silver

    http://www.ncbi.nlm.nih.gov/pubmed/21932165

    Rev Endocr Metab Disord. 2012 Mar;13(1):57-69.

    The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis.

    Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, Haussler CA, Jurutka PW.

    Source



    Department of Basic Medical Sciences, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA. haussler@u.arizona.edu

    Abstract



    1,25-dihydroxyvitamin D (1,25D), through association with the nuclear vitamin D receptor (VDR), exerts control over a novel endocrine axis consisting of the bone-derived hormone FGF23, and the kidney-expressed klotho, CYP27B1, and CYP24A1 genes, which together prevent hyperphosphatemia/ectopic calcification and govern the levels of 1,25D to maintain bone mineral integrity while promoting optimal function of other vital tissues. When occupied by 1,25D, VDR interacts with RXR to form a heterodimer that binds to VDREs in the region of genes directly controlled by 1,25D (e.g., FGF23, klotho, Npt2c, CYP27B1 and CYP24A1). By recruiting complexes of comodulators, activated VDR initiates a series of events that induces or represses the transcription of genes encoding proteins such as: the osteocyte-derived hormone, FGF23; the renal anti-senescence factor and protein co-receptor for FGF23, klotho; other mediators of phosphate transport including Npt2a/c; and vitamin D hormone metabolic enzymes, CYP27B1 and CYP24A1. The mechanism whereby osteocytes are triggered to release FGF23 is yet to be fully defined, but 1,25D, phosphate, and leptin appear to play major roles. The kidney responds to FGF23 to elicit CYP24A1-catalyzed detoxification of the 1,25D hormone while also repressing both Npt2a/c to mediate phosphate elimination and CYP27B1 to limit de novo 1,25D synthesis. Comprehension of these skeletal and renal actions of 1,25D should facilitate the development of novel mimetics to prevent ectopic calcification, chronic renal and vascular disease, and promote healthful aging.
     
  4. chocolate

    chocolate Silver

    http://www.ncbi.nlm.nih.gov/pubmed/21985980

    Vitamin D deficiency and primary hyperparathyroidism.

    Nuti R, Merlotti D, Gennari L.

    Source



    Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Viale Braccci, 53100 Siena, Italy. nutir@unisi.it

    Abstract



    Vitamin D via its receptor has essential actions on parathyroid cells, inhibiting PTH secretion, and parathyroid cell proliferation. While the effects of vitamin D depletion in the pathogenesis of secondary hyperparathyroidism in elderly individuals or in the occurrence of parathyroid hyperplasia in patients with renal insufficiency are well established, the association between hypovitaminosis D and primary hyperparathyroidism (P-HPT) has only recently become appreciated.
    In different cohorts of patients with P-HPT, vitamin D deficiency has been recently associated with higher PTH levels, larger adenomas, and a more severe phenotype (including osteitis fibrosa cystica) as well as negative post-operative outcomes following parathyroidectomy. Despite current guidelines recommend measurement of serum 25OHD (25-hydroxy-cholecalciferol) in P-HPT and their repletion if the levels are
     
  5. chocolate

    chocolate Silver

  6. chocolate

    chocolate Silver

    http://www.forbes.com/sites/larryhusten/2012/06/21/olmesartan-use-associated-with-gi-disorder-that-mimics-celiac-disease/


    More details in the article.





    I wonder if the doctors even know about the Marshal Protocol? the whole point of using the olmesmartan is to kick loose virii from the vitamin d receptor and activate the innate immune system. The point of the gut leaking in two directions is to get rid of viruii as well. They have to leave somehow. Just wondering the thought process.
     
  7. Jack Kruse

    Jack Kruse Administrator

    This is more disruption of DPPIV.......by olmesmartan.......We talked about this in the comments of BG 1 and BG 2.......celiac is not the only thing that disrupts DPPIV
     
    rlee314 likes this.
  8. chocolate

    chocolate Silver

    http://en.wikipedia.org/wiki/Dipeptidyl_peptidase-4_inhibitor



     
  9. chocolate

    chocolate Silver

    http://www.benthamscience.com/contents-JCode-CDR-Vol-00000007-Iss-00000001.htm







     
  10. chocolate

    chocolate Silver

    I read that before, and forgot all about it. I quit taking it because of the high calcium symptoms. Stupid of me. We are back on the vitamin with meals only. And targeting the renin angiotensin system, along with everything else in the chain we can find.
     

Share This Page